Skip to main content
. 2020 Oct 10;1228:129433. doi: 10.1016/j.molstruc.2020.129433

Fig. 1.

Fig 1

The required structural features for a good covalent as well as non-covalent SARC—CoV-2 Mpro inhibitor.